Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06966479 · ClinicalTrials.gov registry record · Phase 2

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

A Phase 2 study of Severe Asthma, sponsored by Upstream Bio.

Recruiting
Registry status
Phase 2
Development phase
436
Enrollment target
20
Study locations

NCT06966479 is a Phase 2 study of Severe Asthma that is actively recruiting participants, run by Upstream Bio. The registered enrollment target is 436 participants, below the 3,806-participant average among 9 other Severe Asthma trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06966479, a Phase 2 study of Severe Asthma, is actively recruiting participants, sponsored by Upstream Bio.

RECRUITING
Registry status
Phase 2
Development phase
436 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).

Conditions Studied

Severe Asthma

Interventions

  • DRUG Placebo
  • DRUG Verekitug

Study Locations (20)

Florida

  • Advance Pharma Research - Cutler Bay
  • Phoenix Medical Research - Miami
  • Research Institute of South Florida - Miami
  • Health and Life Research Institute, LLC - Miami
  • Nouvelle Clinical Research - Miami
  • Edward Jenner Research Group, LLC - Plantation
  • R&B Medical Center - Tampa
  • Clinical Site Partners dba Flourish research - Winter Park

California

  • Kern Research, Inc. - Bakersfield
  • California Medical Research Associates Inc. - Northridge
  • Integrated Research of Inland Inc - Upland
  • Allergy & Asthma Clinical Research - Walnut Creek
  • Allianz Research Institute - Westminster

Michigan

  • Pulmonary Research Institute of Southeast Michigan (PRISM) - Farmington Hills
  • AA MRC - Flint

Idaho

  • Treasure Valley Medical Research - Boise

Maryland

  • Chesapeake Clinical Research Inc - White Marsh

Nevada

  • M3 Wake Research - Las Vegas

New York

  • Urban Health Plan INC - The Bronx

Ohio

  • Toledo Institute of Clinical Research Inc - Toledo

Trial Details

FieldValue
Enrollment Target 436 participants
Start Date 2025-05-21
Est. Completion 2027-09
Phase Phase 2

Sponsor

Upstream Bio

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06966479

The ClinicalTrials.gov registry entry for NCT06966479 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 436 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,806-participant average among 9 other Severe Asthma trials with a reported enrollment target (89% lower). The listed sponsor is Upstream Bio, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Severe Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06966479 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT06966479 about?

NCT06966479 is a clinical study titled "A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)". The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).

What is the current status of trial NCT06966479?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 436 participants. The study started on 2025-05-21. Estimated completion is 2027-09.

What conditions does trial NCT06966479 study?

This clinical trial studies the following conditions: Severe Asthma.

What interventions are being tested in trial NCT06966479?

The interventions under investigation include: Placebo (DRUG), Verekitug (DRUG).

Who is sponsoring clinical trial NCT06966479?

This trial is sponsored by Upstream Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06966479 being conducted?

This trial has 20 study locations across California, Florida, Idaho, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Severe Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Severe Asthma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.